Browsing Tag
Orbit study
1 post
Ultragenyx Pharmaceutical faces shareholder litigation risks after Orbit study update triggers stock plunge
Ultragenyx faces legal probe and investor scrutiny after a 25% stock drop tied to delayed Phase 3 Orbit study data for UX143. Learn what analysts expect next.